Frontlight ResearchEarly access
Melanoma trials in China
66 of 70 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Phase II Study of Nab-Paclitaxel Combined With Retlirafusp Alfa and Apatinib in Patients With Advanced Mucosal Melanoma
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 27
- Run by
- Sun Yat-sen University
See details and how to joinNCT07934927 - Phase 4CompletedDabrafenib and/or Trametinib Rollover Study
- Where
- Beijing
- Age
- 18 years to 100 years
- People
- 100 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00 - Phase 2Taking peopleA Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Where
- Beijing, Chongqing, Guangzhou, Shanghai, Xinxiang
- Age
- 18 years and over
- People
- 254 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07492680 - Phase 1/2Not yet taking people in ChinaCombination Immunotherapy Targeting Melanoma
- Where
- Shenzhen
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT06739226 - Phase 2Taking peopleDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- Beijing, Changsha, Chengdu, Dongguan, Henan, Hubei, Shanghai, Shenyang, Wuhan, Xi'an, Xinxiang, Xuzhou
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - Phase 1/2Taking peopleA Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other Solid Tumors
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07841925 - Phase 2Taking peopleHS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma（FASTIL-Mela02）
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 90
- Run by
- Hangzhou Huasai Biomedicine Co., Ltd.
See details and how to joinNCT07406724 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Chengdu, Guangzhou
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 1/2Taking peopleA Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Where
- Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Taizhou, Tianjin, Wuhan, Xi’an, Xinxiang, Zhengzhou
- Age
- 18 years and over
- People
- 862 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT05914116 - Phase 1/2Taking peopleA Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.
- Where
- Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Kunming, Nanjing, Nanning, Shanghai, Taiyuan, Tianjin, Wuhan, Xi'an
- Age
- 18 years and over
- People
- 280
- Run by
- Nanjing Leads Biolabs Co.,Ltd
See details and how to joinNCT07099430 - No phaseTaking people68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
- Where
- Beijing
- Age
- 18 years and over
- People
- 50
- Run by
- Peking University Third Hospital
See details and how to joinNCT07760012 - Phase 1Taking peopleSafety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
- Where
- Beijing
- Age
- 18 years and over
- People
- 167
- Run by
- Shandong Boan Biotechnology Co., Ltd
See details and how to joinNCT06596915 - Phase 1/2Taking peopleA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Where
- Chongqing, Hangzhou, Tianjin, Wuhan
- Age
- 18 years and over
- People
- 1,438 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00 - Phase 2Taking peopleCryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 28
- Run by
- Sun Yat-sen University
See details and how to joinNCT07847359 - Phase 2Taking peopleClinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes
- Where
- Beijing
- Age
- 18 years and over
- People
- 50
- Run by
- Peking University Cancer Hospital & Institute
See details and how to joinNCT07848243 - Phase 1Taking peopleA Study of DXC014 in Patients With Advanced Solid Tumors.
- Where
- Beijing, Changsha, Hangzhou, Nanchang, Qingdao
- Age
- 18 years and over
- People
- 150
- Run by
- Hangzhou DAC Biotechnology Co., Ltd.
See details and how to joinNCT07177937 - Phase 1Not yet taking people in ChinaAu-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy
- Where
- Chengdu
- Age
- 18 years and over
- People
- 6
- Run by
- West China Hospital
See details and how to joinNCT07562841 - Phase 2Taking peopleSintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery
- Where
- Changchun
- Age
- 18 years and over
- People
- 220
- Run by
- The First Hospital of Jilin University
See details and how to joinNCT07400302 - Phase 1Taking peopleA Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- Where
- Beijing, Haerbin, Linyi, Shanghai
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Pierre Fabre Medicament
See details and how to joinNCT04913285 - Phase 2Taking peopleA Phase II Trial of LM103 in Advanced Melanoma
- Where
- Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xi'an, Zhengzhou
- Age
- 18 years to 75 years
- People
- 92
- Run by
- Suzhou BlueHorse Therapeutics Co., Ltd.
See details and how to joinNCT07310784 - Phase 1/2Taking peoplePhase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors
- Where
- Beijing
- Age
- 18 years and over
- People
- 500
- Run by
- Shanghai JMT-Bio Inc.
See details and how to joinNCT07280832 - Phase 2Taking peopleTunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 37
- Run by
- Sun Yat-sen University
See details and how to joinNCT07750067 - Phase 1/2Taking peopleA Clinical Study of T3011 in Subjects With Advanced Melanoma
- Where
- Beijing, Bengbu, Changchun, Chengdu, Fuzhou, Zhengzhou, Zhongshan
- Age
- 18 years and over
- People
- 42
- Run by
- Shanghai Pharmaceuticals Holding Co., Ltd
See details and how to joinNCT06214156 - Phase 2Taking peopleA Study of GC101 TIL in Advanced Melanoma
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 98
- Run by
- Shanghai Juncell Therapeutics
See details and how to joinNCT06703398 - Phase 2Taking peopleA Study of IBI363 in Subjects With Advanced Melanoma
- Where
- Beijing, Changchun, Changsha, Fuzhou, Jinan, Kunming, Nanchang, Nanjing, Taiyuan, Zhengzhou
- Age
- 18 years and over
- People
- 180
- Run by
- Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT06081920